Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 119Squamous Cell Carcinoma of Head and Neck 60Melanoma 57Parkinson Disease 4, Autosomal Dominant Lewy Body 46Lung Neoplasms 45Triple Negative Breast Neoplasms 44Neoplasm Metastasis 42Breast Neoplasms 40Neoplasms 36Colorectal Neoplasms 31Head and Neck Neoplasms 27Endometrial Neoplasms 26Carcinoma, Renal Cell 26Ovarian Neoplasms 23Carcinoma, Transitional Cell 22Urinary Bladder Neoplasms 20Stomach Neoplasms 15Carcinoma 14Pancreatic Neoplasms 13Uterine Cervical Neoplasms 12Recurrence 12Esophageal Neoplasms 12Sarcoma 11Hodgkin Disease 11Brain Neoplasms 11Carcinoma, Squamous Cell 10Cholangiocarcinoma 9Carcinoma, Hepatocellular 9Skin Neoplasms 8Esophageal Squamous Cell Carcinoma 8

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Jaw Neoplasms × pembrolizumab × 90 days × Clear all
NCT07552558 2026-06-03

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Washington University School of Medicine

Phase 1/2 Not yet recruiting
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Jaw Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡